|
|
|
| Relationship between chemotherapy efficacy and neutrophil to lymphocyte ratio in advanced non-small cell lung cancer |
| CAO Yuhua1 LYU Yanru1 HAO Yanrong1 MO Xiaoyun2 FENG Guosheng1 HUANG Lu1 CHEN Xiaodan1 GAO Shan1 LU Shui1 |
1.Chemotherapy District One, Clinical Oncology Center, the People’s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region, Nanning 530021, China;
2.Department of Clinical Research, the People’s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region, Nanning 530021, China |
|
|
|
Abstract Objective To investigate the relationship between the neutrophil to lymphocyte ratio （NLR） and chemotherapy efficacy in advanced non-small cell lung cancer （NSCLC）. Methods A retrospective analysis of 80 NSCLC inpatients with inoperable stage ⅢB and Ⅳ who met the enrollment criteria in the People’s Hospital of Guangxi Zhuang Autonomous Region from January 2016 to January 2020. NLR was collected before treatment, and the relationship between NLR and chemotherapy efficacy was analyzed. According to the treatment effect, the patients were divided into the curative effect response group and the curative effect non-response group. Results Univariate analysis showed that there was a statistically significant difference in NLR between the two groups (P < 0.05). Multi-factor regression analysis showed that NLR was an independent risk factor affecting the effect of chemotherapy (OR > 1, P < 0.05). Conclusion The efficacy of chemotherapy is related to pre-treatment NLR, and the chemotherapy efficacy is better in patients with lower NLR. NLR may be an index to predict the efficacy of first-line chemotherapy in advanced NSCLC.
|
|
|
|
|
|
[1] 郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2019，41（1）：19-28.
[2] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[3] Torre LA，Siegel RL，Jemal A. Lung Cancer Statistics [J]. Adv Exp Med Biol，2016，893：1-19.
[4] Gou LY，Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China [J]. Lung Cancer ：Auckl，2014，5（default）：1-9.
[5] Shankaran V， Ikeda H，Bruce AT，et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity [J]. Nature，2001，410（6832）：1107-1111.
[6] Coussens LM，Werb Z. Inflammation and cancer [J]. Nature，2002，420（6917）：860-867.
[7] Lu Y，Jiang J，Ren C. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer：A meta-analysis [J]. PLoS One，2020，15（4）：e0230979.
[8] Liu D，Jin J，Zhang L，et al. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer [J]. Cell Physiol Biochem，2018，46（4）：1595-1605.
[9] Ke TM，Lin LC，Huang CC，et al. High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy [J]. Medicine：Baltimore，2020，99（17）：e19877.
[10] Dan J，Tan J，Huang J，et al. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients [J]. Breast Cancer，2020，27（5）：982-988.
[11] Miyagawa Y，Yanai A，Yanagawa T，et al. Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer [J]. Oncotarget，2020，11（1）：86-98.
[12] Zhao G，Liu N，Wang S，et al. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer [J]. Medicine：Baltimore，2020，99（10）：e19405.
[13] Yamada T，Hayashi T，Inokuchi Y，et al. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy [J]. Target Oncol，2020，15（3）：317-325.
[14] Miyamoto R，Inagawa S，Sano N，et al. The neutrophil-to-lymphocyte ratio（NLR）predicts short-term and long-term outcomes in gastric cancer patients [J]. Eur J Surg Oncol，2018，44（5）：607-612.
[15] Gundog M，Basaran H. The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in nasopharyngeal cancer [J]. J Buon，2020，25（1）：367-375.
[16] Jiang Y，Qu S，Pan X，et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in intensity modulated radiation therapy for nasopharyngeal carcinoma [J]. Oncotarget，2018，9（11）：9992-10004.
[17] Ono T，Igawa S，Kurahayashi S，et al. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors [J]. Invest New Drugs，2020，38（3）：885-893.
[18] Phan TT，Ho TT，Nguyen HT，et al. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI [J]. Int J Gen Med，2018，11：423-430.
[19] Russo A，Franchina T，Ricciardi GRR，et al. Baseline neutrophilia， derived neutrophil-to-lymphocyte ratio（dNLR），platelet-to-lymphocyte ratio（PLR），and outcome in non small cell lung cancer（NSCLC）treated with Nivolumab or Docetaxel [J]. J Cell Physiol，2018，233（10）：6337-6343.
[20] 易福梅，顾春阳，陈森，等.治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J].中国肺癌杂志，2018，21（6）：481-492.
[21] Detterbeck FC，Boffa DJ，Tanoue LT. The new lung cancer staging system [J]. Chest，2009，136（1）：260-271.
[22] Nishino M，Jackman DM，Hatabu H，et al. New Response Evaluation Criteria in Solid Tumors（RECIST）guidelines for advanced non-small cell lung cancer：comparison with original RECIST and impact on assessment of tumor response to targeted therapy [J]. AJR Am J Roentgenol，2010，195（3）：W221-W228.
[23] Ietomi K. A study on the role of granulocytes in carcinoma-bearing hosts-G/L ratio as a new host indicator [J]. Nippon Gan Chiryo Gakkai shi，1990，25（3）：662-671.
[24] Liu J，Li S，Zhang S，et al. Systemic immune-inflammation index，neutrophil-to-lymphocyte ratio，platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab [J]. J Clin Lab Anal，2019，33（8）：e22964.
[25] 乔建兵，戴宏宇，徐春华，等.炎症因子评分对晚期非小细胞肺癌患者预后评估的应用价值[J].江苏大学学报：医学版，2019，29（5）：430-435. |
|
|
|
